✦ LIBER ✦
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
✍ Scribed by D. Sargent; Q. Shi; G. Yothers; E. Van Cutsem; J. Cassidy; L. Saltz; N. Wolmark; B. Bot; A. Grothey; M. Buyse; A. de Gramont
- Book ID
- 116430646
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 226 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0959-8049
No coin nor oath required. For personal study only.